enGene Therapeutics (ENGN) Insider Lota Zoth Buys 31,000 Shares
Lota Zoth purchased 31,000 shares of enGene Therapeutics Inc. on June 16, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Lota Zoth bought 31,000 shares of enGene Therapeutics Inc. ($ENGN) on June 16, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $ENGN is down 2.3% after 1 week, up 9.7% after 1 month and down 4.6% to date (from the $1.75 close on Jun 16, 2026).
ENGN
enGene Therapeutics Inc.
Key Points
- Lota Zoth bought 31,000 shares of enGene Therapeutics Inc. on June 16, 2026, with no disclosed transaction value.
- enGene Therapeutics, trading on NasdaqCM under ENGN, has a market cap of approximately $117.2 million and a 52-week range between $1.40 and $12.25.
- The company focuses on genetic treatments for bladder cancer and has a forward P/E ratio that is not meaningful due to negative earnings.
Get $ENGN trade alerts by text
We text you when insiders, Congress or big funds trade $ENGN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated enGene Therapeutics Inc. alert may contain errors. Disclosures
On June 16, 2026, Lota Zoth acquired 31,000 shares of enGene Therapeutics Inc. (NasdaqCM:ENGN). The transaction did not have a disclosed value, and the stock was trading around $1.75 at the time.
enGene Therapeutics Inc. Stock Down 8.9%
Shares of enGene Therapeutics Inc. are listed on the Nasdaq Capital Market under the ticker ENGN. The company has a market capitalization of about $117.2 million. Its shares have traded as low as $1.40 and as high as $12.25 over the past year. The stock's 50-day moving average is approximately $4.33, while the 200-day moving average is around $7.13. enGene has a current ratio of 12.57 and a quick ratio of 12.07, with a debt-to-equity ratio of 13.07.
About enGene Therapeutics Inc.
enGene Therapeutics Inc. is a biotechnology company based in Montreal, Canada. It specializes in developing genetic medicines, focusing on treatments for bladder cancer. The company's lead product candidate, detalimogene voraplasmid, is aimed at treating non-muscle invasive bladder cancer. enGene also has another product, LEGEND, which is in Phase 2 trials. The company was previously known as enGene Holdings Inc. and adopted its current name in April 2026. Under the leadership of CEO Ronald H. W. Cooper, enGene employs 81 people.
Bottom Line
Lota Zoth's recent purchase of shares in enGene Therapeutics highlights ongoing interest in the company, despite its current challenges. enGene is focused on innovative treatments for bladder cancer, a niche that could offer potential growth opportunities. Investors will continue to monitor the company's progress as it moves forward with its clinical trials. As always, it's important to note that insider transactions are disclosed after they occur and may not reflect future actions.
Related Filing Alerts
Source: Lota Zoth's Form 4 filing on $ENGN (Jun 16, 2026). Find the original filing: ENGN Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts